Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial

PURPOSE: Macrophages are critical in driving an immunosuppressive tumor microenvironment that counteracts the efficacy of T-cell–targeting therapies. Thus, agents able to reprogram macrophages toward a proinflammatory state hold promise as novel immunotherapies for solid cancers. Inhibition of the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Virtakoivu, Reetta, Rannikko, Jenna H., Viitala, Miro, Vaura, Felix, Takeda, Akira, Lönnberg, Tapio, Koivunen, Jussi, Jaakkola, Panu, Pasanen, Annika, Shetty, Shishir, de Jonge, Maja J.A., Robbrecht, Debbie, Ma, Yuk Ting, Skyttä, Tanja, Minchom, Anna, Jalkanen, Sirpa, Karvonen, Matti K., Mandelin, Jami, Bono, Petri, Hollmén, Maija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401456/
https://www.ncbi.nlm.nih.gov/pubmed/34078651
http://dx.doi.org/10.1158/1078-0432.CCR-20-4862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401456/
https://www.ncbi.nlm.nih.gov/pubmed/34078651
http://dx.doi.org/10.1158/1078-0432.CCR-20-4862

Ejemplares similares